Thymosin Alpha-1 — 10mg

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally secreted by thymic epithelial cells, where it plays a central role in T-lymphocyte differentiation and maturation. It was first isolated and characterized by Allan Goldstein in the 1970s and has since accumulated one of the most extensive clinical evidence bases of any immunomodulatory peptide — including regulatory approval as Zadaxin in over 35 countries for applications ranging from chronic hepatitis B and C treatment to cancer immunotherapy adjuvancy.

At the receptor level, Tα1 binds Toll-Like Receptors 3, 4, and 9 on dendritic cells and macrophages, activating both IRF3-dependent interferon signaling and NF-kB-mediated inflammatory gene programs. This dual activation drives dendritic cell maturation, enhances antigen presentation to T-cells, and increases natural killer cell cytotoxicity — effectively raising the overall surveillance and effector capacity of the adaptive and innate immune systems in concert. Its ability to promote naïve T-cell differentiation toward Th1 phenotypes makes it particularly relevant to chronic viral infections and cancer contexts where Th2 bias or immune exhaustion has developed.

The compound's vaccine adjuvant properties are well-documented: co-administration of Tα1 with hepatitis B vaccines improved seroconversion rates in non-responders, and similar effects have been observed with influenza vaccines in elderly immunosenescent populations. The immunosenescence application — restoring immune function in aged individuals to levels resembling younger immune profiles — represents one of the most active current research directions, particularly in the context of susceptibility to infection and reduced vaccine efficacy in aging populations.